Coadministration of estrogen with estrogen receptor modulator or degrader or er targeted protac for the treatment of estrogen responsive cancers
OwnerDonald P. McDonnell, Suzanne E. Wardellinventors
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods for treating cancer. The methods may include administering to a subject at least one brain-excluded estrogen receptor (ER) modulating drug. The methods may further include administering to the subject at least one brain-penetrating ER agonist or at least one brain-penetrating androgen receptor (AR) modulator. The brain-excluded ER modulating drug may be administered to a subject at a dose that results in from zero to minimal brain exposure.
Claims37
A method of treating cancer in a subject, the method comprising administering to the subject at least one brain-excluded estrogen receptor (ER) modulating drug such that the drug exposure in the brain is zero to minimal.
A method of inhibiting an estrogen receptor (ER) peripherally in a subject but not in the brain, the method comprising administering to the subject at least one brain-excluded estrogen receptor (ER) modulating drug such that the drug exposure in the brain is zero to minimal.
A composition for treating cancer, the composition comprising at least one brain-excluded estrogen receptor (ER) modulating drug and at least one brain-penetrating ER agonist.
A composition for treating cancer, the composition comprising at least one brain-excluded estrogen receptor (ER) modulating drug and at least one brain-penetrating androgen receptor (AR) modulator.
Dependencies are inferred from the claim text.